This Article Abstract Full Text (PDF) Methods Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bezzina, C. Articles by Wilde, A. A. M. Search for Related Content PubMed PubMed Citation Articles by Bezzina, C. Articles by Wilde, A. A. M.

(Circulation Research. 1999;85:1206.)
© 1999 American Heart Association, Inc.

Clinical Research

A Single Na⁺ Channel Mutation Causing Both Long-QT and Brugada Syndromes

Connie Bezzina¹, Marieke W. Veldkamp¹, Maarten P. van den Berg, Alex V. Postma, Martin B. Rook, Jan-Willem Viersma, Irene M. van Langen, Ghita Tan-Sindhunata, Margreet Th. E. Bink-Boelkens, Annemarie H. van der Hout, Marcel M. A. M. Mannens, Arthur A. M. Wilde

From the Departments of Clinical Genetics (C.B., A.V.P., I.M.v.L, M.M.A.M.M.) and Experimental and Molecular Cardiology (C.B., A.V.P., M.W.V., A.A.M.W.), Academic Medical Center, Amsterdam; Departments of Cardiology (M.P.v.d.B, J.-W.V.), Medical Genetics (G.T.-S., A.H.v.d.H.), and Paediatrics (M.Th.E.B.-B.), Groningen University Hospital, Groningen; Departments of Medical Physiology (M.B.R.) and Cardiology (A.A.M.W.), Utrecht University Hospital, Utrecht, the Netherlands; and the Interuniversity Cardiology Institute of the Netherlands (A.A.M.W.).

Correspondence to Dr A.A.M. Wilde, Department of Clinical and Experimental Cardiology, AMC, PO Box 22700, 1100 DE Amsterdam, the Netherlands. E-mail a.a.wilde{at}amc.uva.nl

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Abstract—Mutations in SCN5A, the gene encoding the cardiac Na⁺ channel, have been identified in 2 distinct diseases associated with sudden death: one form of the long-QT syndrome (LQT₃) and the Brugada syndrome. We have screened SCN5A in a large 8-generation kindred characterized by a high incidence of nocturnal sudden death, and QT-interval prolongation and the "Brugada ECG" occurring in the same subjects. An insertion of 3 nucleotides (TGA) at position 5537, predicted to cause an insertion of aspartic acid (1795insD) in the C-terminal domain of the protein, was linked to the phenotype and was identified in all electrocardiographically affected family members. ECGs were obtained from 79 adults with a defined genetic status (carriers, n=43; noncarriers, n=36). In affected individuals, PR and QRS durations and QT intervals are prolonged (P<0.0001 for all parameters). ST segment elevation in the right precordial leads is present as well (P<0.0001). Twenty-five family members died suddenly, 16 of them during the night. Expression of wild-type and mutant Na⁺ channels in Xenopus oocytes revealed that the 1795insD mutation gives rise to a 7.3-mV negative shift of the steady-state inactivation curve and an 8.1-mV positive shift of the steady-state activation curve. The functional consequence of both shifts is likely to be a reduced Na⁺ current during the upstroke of the action potential. LQT₃ and Brugada syndrome are allelic disorders but may also share a common genotype.

Key Words: long-QT syndrome • Brugada syndrome • SCN5A • arrhythmia • Na⁺ channel

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
SCN5A, the gene that encodes the human cardiac Na⁺ channel subunit,¹ is mutated in one form of the long-QT syndrome (LQT₃) and in Brugada syndrome.^{2 3} There are characteristic and readily distinguishable ECG patterns in these 2 syndromes. In LQT₃ patients, a long isoelectric ST segment precedes a peaked T wave.⁴ Brugada syndrome is diagnosed on the basis of characteristic ECG features in the absence of structural heart disease; these features include right precordial ST-segment elevation, which may be intermittent, and which is exacerbated by Na⁺ channel block and ameliorated by isoproterenol.^{5 6} QT intervals have been reported to be normal in patients with Brugada syndrome.⁵ Clinically, there appears to be some overlap between the 2 syndromes, as both exhibit a relatively high incidence of nocturnal sudden cardiac death without prior symptoms.^{6 7 8}

The prolonged QT interval in LQT₃ results from persistent inward Na⁺ current during the plateau phase of the action potential, secondary to incomplete inactivation of mutated channels.⁹ Changes in the and ß₁ subunit interaction have also been implicated.¹⁰ Although functional abnormalities have been described for Brugada syndrome–related SCN5A mutant channels,^{3 11} the mechanism(s) whereby these explain the Brugada phenotype are less clear.

In this study we present clinical and genetic data of a single large SCN5A-linked family, phenotypically characterized by nocturnal death and electrocardiographically by both LQT₃ and Brugada syndrome features in the same patients. We show that LQT₃ and the Brugada syndrome are more closely related than heretofore appreciated and can even be caused by the same mutation. We also report on the functional consequences of the Na⁺ channel mutation involved, as revealed by measuring Na⁺ channel activity in the Xenopus oocyte expression system.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Patients
The study was performed according to a protocol approved by the local ethics committees. Informed consent was obtained from all patients, who were all screened by one of us. For purposes of linkage analysis, the phenotype was assigned in a subset of the family according to the criteria described in the online Materials and Methods (see http://www.circresaha.org).

After the mutation was identified (see below), a careful history, an ECG at rest and in the supine position, and peripheral blood samples for genotype analysis were taken from as many other family members as possible. Patients with specific reasons for prolongation of the QT interval were excluded from further (electrocardiographic) analysis. We analyzed 12-lead ECGs (paper speed, 25 mm/s), only of patients 16 years of age, with particular reference to rate and to PR, QRS, and QT interval (the longest interval in any lead was taken). QTc was calculated according to the Bazett formula. In the final analysis, mutation carriers either are obligate carriers (by pedigree analysis) or have a proven genetic status (see below). Individuals within this family from which no DNA or ECGs were available were defined as mutation carriers when they died suddenly and unexpectedly under typical circumstances (see below).

Signal-averaged electrocardiography (SAECG) was performed in the supine position according to the method previously described for a subset of these patients.¹² We considered the SAECG abnormal according to the predefined criteria.¹² In 5 individuals, an invasive electrophysiological study by standard procedures was performed.

Linkage Analysis
Genotyping of microsatellite markers around the known LQT (SCN5A, LQT₄, HERG, KCNQ1, and KCNE1) and Brugada syndrome (SCN5A) loci was performed by standard, semiautomated methods. Linkage analyses were carried out using the MLINK program from the LINKAGE 5.1 package.

Mutation Analysis of SCN5A
Mutation analysis of SCN5A was done by single-strand conformation polymorphism (SSCP) analysis followed by direct sequence analysis of aberrant conformers. All 28 exons of the SCN5A gene were amplified using intronic primers designed by Wang et al¹³ and analyzed in this way. Independent of the outcome of SSCP analysis, 12 exons (2, 3, 12, 17–21, 24, 26–28) were also analyzed by direct sequence analysis.

Functional Expression
Mutant Na⁺ channel cDNA was prepared by mutagenesis on the double-stranded pSP64T-hH1(sp) plasmid.^{1 14} Wild-type (WT) and mutant constructs were linearized and cRNAs were synthesized. cRNA concentration was determined spectrophotometrically at a 260-nm wavelength.

Electrophysiology
Stage V through VI Xenopus oocytes were isolated and injected with 5 to 20 ng of cRNA according to standard methods.¹⁵ Voltage-clamp experiments were performed 2 to 4 days after injection, using a Geneclamp 500 2-electrode voltage clamp amplifier (Axon Instruments). Na⁺ currents were corrected for leakage current using Geneclamp leak subtraction. Steady-state activation and inactivation parameters were determined using protocols similar to those published previously by Wang et al.¹⁶ Electrophysiological experiments were performed at room temperature (21°C).

Statistical Analysis
Differences between groups (mutation carriers and noncarriers) were compared by the Fischer exact test or unpaired Student t test, where appropriate. A 2-tailed probability value of <0.05 was considered statistically significant. In electrophysiological studies, differences between WT Na⁺ current and mutant Na⁺ current were compared using the unpaired Student t test.

An expanded Materials and Methods section is available online at http://www.circresaha.org.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
The anonymized pedigree of the family is presented in Figure 1. Linkage analysis in a subset of the family (11 affected and 12 unaffected) revealed linkage to SCN5A (Table 1), whereas no evidence of linkage was detected to the LQT₄, HERG, KCNQ1, and KCNE1 loci. Subsequent SSCP analysis of the coding region of SCN5A using primers flanking the exon-intron boundaries identified an aberrant conformer in exon 28 in affected family members (Figure 2; n=53, including children). The aberrant conformer was not present in unaffected family members nor in 100 alleles from unrelated control individuals. DNA sequencing of exon 28 of affected family members revealed heterozygosity for a TGA insertion at position 5537. This insertion results in the insertion of aspartate after tyrosine 1795 (1795insD) within the highly negatively charged region of the C-terminal domain of the protein. SSCP analysis of all the other exons and direct sequence analysis of a large part of the coding region (see Materials and Methods) in 3 affected individuals (VI-27, VI-29, and VI-30) revealed no further abnormalities.

View larger version (18K): [in this window] [in a new window]   Figure 1. Pedigree of the family. Seven generations are presented (for reasons of privacy, the eighth generation is not depicted). Persons identified by genotype analysis as carriers of the 1795insD mutation are indicated by filled circles (females) or squares (males). Further explanation is given in the figure. The pedigree has been altered to protect confidentiality.

View this table: [in this window] [in a new window]   Table 1. Linkage Analysis of Chromosome 3p21 Markers and the Affected Status

View larger version (45K): [in this window] [in a new window]   Figure 2. Insertion of 3 nucleotides (TGA) at position 5537, resulting in the addition of aspartic acid in the SCN5A protein of affected individuals. A, Representative part of the pedigree (for symbols see Figure 1). B, SSCP analysis of exon 28 of SCN5A, with a distinct shift (arrow) in mutation carriers. C, Sequence analysis of exon 28 of SCN5A in mutation carriers and non–mutation carriers, showing the insertion of TGA resulting in the addition of aspartic acid after the tyrosine at position 1795 of the SCN5A protein (arrow).

We were able to trace the history of 203 family members in 8 generations (Figure 1). ECGs were obtained from 119 individuals, of whom 79 adults had a defined genetic status (mutation carriers, n=43; noncarriers, n=36). Figure 3 demonstrates an example (patient VI-27). Heart rate is relatively slow, PR and QRS durations are slightly prolonged, and the QT interval is markedly prolonged (Figure 3B). In the right precordial leads, ST-segment elevation is apparent (Figure 3A). Table 2 summarizes basic demographic and electrocardiographic data of the 79 genotyped family members. Whereas sex and age are similar in affected and nonaffected members, mean heart rate is slightly lower (P<0.02), and conduction parameters (PR and QRS intervals) are slightly prolonged in mutation carriers (for both parameters; P<0.0001). In addition, HV interval was prolonged in 4 of the 5 carriers in whom an invasive electrophysiological study was performed: 58, 78, 75, and 80 ms in V-1, VI-27, VI-54, and VI-60 respectively, and 50 in VI-3. SAECG was abnormal in 23 of 29 mutation carriers tested (79%) and abnormal in 2 of 14 noncarriers (14%; P<0.001). Figure 4 depicts normalized QT intervals (QTc) versus heart rate in analyzed patients. QTc was clearly prolonged in the vast majority of mutation carriers, in particular in those in whom heart rate is slow. PR and QRS prolongation was concomitantly present in 14 carriers, whereas only PR or only QRS prolongation was seen in 10 carriers (and in 6 noncarriers) and 10 carriers (and in 1 noncarrier), respectively (Figure 5A). ST-segment elevation was present in 21 of the 43 carriers versus 3 of 36 noncarriers (P<0.001; mean values in Table 2). Figure 5B shows QTc intervals versus ST segment elevation in individuals. In 16 carriers, both QTc is prolonged and right precordial ST segments are elevated. In 13 carriers, only QTc was prolonged, whereas in 5 carriers (and 3 noncarriers) only ST-segment elevation was apparent. In all 3 carriers (VI-27, VI-29, and VI-30) who received a bolus procainamide (250 mg IV), ST-segment elevation was increased further (see inset, Figure 3B). There were no echocardiographic abnormalities in 29 mutation carriers.

View larger version (152K): [in this window] [in a new window]   Figure 3. ECG recordings of patient VI-27. A, ECG at first visit. Note the prolonged PR interval and the marked ST-segment elevation in lead V1–3. QTc is slightly prolonged (465 ms). B, During sinus bradycardia (cycle length 1600 ms), QTc prolongs further (QT 670 ms, QTc 530 ms). Inset, Selected recordings (V1–3) are depicted shortly before and after 250 mg of procainamide. Note the increase in ST-segment elevation after drug exposure. Calibrations are standard.

View this table: [in this window] [in a new window]   Table 2. Patient Basic Demographic and ECG Characteristics (mean±SD)

View larger version (14K): [in this window] [in a new window]   Figure 4. QTc vs RR interval in all individuals analyzed (43 mutation carriers [] and 36 noncarriers []). QT intervals are particularly prolonged at long RR intervals. However, also at normal heart rate (RR 600 to 1000 ms), QT interval is prolonged in most carriers.

View larger version (20K): [in this window] [in a new window]   Figure 5. PR vs QRS interval (A) and ST-segment elevation vs QTc (B). A, Upper limit of normal values is indicated by dotted lines. B, Values indicated by dotted lines are those used for the linkage study. Note that exclusively mutation carriers have combined PR and QRS interval prolongation (A) and combined ST-segment elevation and QTc prolongation (B). See text for further discussion.

Unexpected nocturnal sudden cardiac death was the only symptom in this family, occurring in 16 family members since 1905 (10 female, 6 male; see online Table, available at http://www.circresaha.org). Eight patients died suddenly under unknown circumstances. One died in the chair of the barber while being shaved (IV-8). Death was witnessed in 5 cases, occurring between 4:00 and 7:00 AM, and the episodes were characterized by sudden onset of gurgling and gasping, and moaning respiration. Patients were unconscious and could not be awakened. No electrocardiographic recordings are available from these episodes. Previous ECGs were available in 4, all demonstrating bradycardia with significant QT-segment prolongation. Nine victims were obligate carriers of the aberrant gene. Three clinically affected individuals have been evaluated in hospital, and sudden arousal during the early morning hours did not reveal any (additional) electrocardiographic abnormality. The mean age (±SD) of sudden cardiac death victims was 32.3±14.63 (n=22), with 19 individuals 40 years (male/female ratio, 9/10).

To establish the consequences of the 1795insD insertion on the electrophysiological properties of the Na⁺ channel, macroscopic Na⁺ currents (I_Na) were recorded in oocytes injected with cRNA encoding either the WT or the 1795insD mutant Na⁺ channel subunit. Figure 6A shows typical families of Na⁺ current traces elicited by 5-mV depolarizing steps between -90 and +40 mV from a holding potential of -100 mV. There was a striking difference in peak amplitudes between the WT Na⁺ current (I_Na,WT, Figure 6A, left) and the 1795insD mutant Na⁺ current (I_Na,1795, Figure 6A, right), despite the fact that similar amounts of cRNA were injected. The average (±SEM) current-voltage relations in Figure 6B show that the maximal I_Na amplitude was 9.9±1.7 µA (n=14) and 2.2±0.5 (n=22) for I_{Na, WT} and I_Na,1795 respectively. The averaged data were obtained from 6 different batches of oocytes. The much larger peak amplitude of WT Na⁺ currents compared with 1795insD Na⁺ currents was a consistent finding. In addition, the voltage for both the threshold of activation and the maximum peak current was shifted by +5 mV for 1795insD channels. We also determined the steady-state voltage dependence of activation and inactivation for I_Na,WT and I_Na,1795, as illustrated in Figure 6C. The averaged data points of the inactivation curve were fitted with a Boltzmann function with V_1/2 of -78.7 mV and a k of -4.5 for the WT Na⁺ channel (n=21) and a V_1/2 of -86.0 mV and a k of -5.0 for the 1795insD mutant Na⁺ channel (n=22). These results indicate a negative shift of the inactivation curve of the 1795insD mutant by 7.3 mV. The averaged data points of the activation curve were fitted with a Boltzmann function with a V_1/2 of -40.2 mV and a k of 5.3 for the WT Na⁺ channel (n=20) and a V_1/2 of -32.1 mV and a k of 5.7 for the 1795insD mutant Na⁺ channel (n=22), resulting in an 8.1-mV positive shift of the activation curve of the 1795insD mutant. Both shifts will result in a reduced Na⁺ current during the upstroke of the action potential and a reduced Na⁺ window current. Recovery from inactivation (Figure 6D) was slightly, but significantly, slower for the 1795insD mutant channel. When the data were fitted with a single exponential function, mean time constants (±SEM) were 12.2±0.6 ms (n=22) and 14.7±0.7 ms (n=22) for the WT and the 1795insD mutant Na⁺ channel, respectively.

View larger version (28K): [in this window] [in a new window]   Figure 6. Comparison of electrophysiological characteristics of WT and 1795insD mutant Na+ channels expressed in Xenopus oocytes. A, Examples of Na+ current traces elicited by 5-mV progressive step depolarizations between -90 and 40 mV from a holding potential of -100 mV. Left, WT Na+ currents. Right, 1795insD mutant Na+ currents. Note the differences in peak current amplitudes. B, Average current-voltage relationship for the WT (, n=14) and the 1795insD mutant (•, n=22) Na+ channel. Data are mean±SEM. C, Steady-state voltage dependence of activation for WT (, n=20) and 1795insD mutant (•, n=22) Na+ channels, and of inactivation for WT (, n=21) and 1795insD mutant (, n=22) Na+ channels. See text for further discussion. D, Recovery from inactivation of WT () and 1795insD mutant (•) Na+ channels at –100 mV. Inset, Bar histogram showing average time constants for WT (n=22) and 1795insD mutant (n=22) Na+ channels. See text for further discussion. *P<0.05.

Because LQT₃ has been associated with incomplete inactivation of the Na⁺ channel, resulting in a persistent Na⁺ current, we sought to determine whether a reduced rate of inactivation or incomplete inactivation was also present in our 1795insD mutant Na⁺ channel. I_Na,WT and I_Na,1795 were recorded at -20 mV, and current decay was fitted with either a single- or double-exponential function (not shown). The results showed that both the fast and the slow time constant of inactivation were only slightly, and not significantly, larger for the 1795insD Na⁺ channel (mean±SEM, WT: _fast=0.98±0.06, _slow=7.1±0.7 [n=20]; 1795insD: _fast=1.15±0.06, _slow=10.49±2.9 [n=22]). Also, the study of procainamide- and tetrodotoxin-sensitive 1795insD Na⁺ currents did not reveal the presence of a persistent inward current. Because 1795insD Na⁺ currents were of very small amplitude, we considered the possibility that a persistent inward current, usually <2% of the peak current, was too small to distinguish. Unfortunately, attempts to increase the expression level by injecting 5 to 10 times higher amounts of cRNA increased peak 1795insD Na⁺ currents no further than 3 µA.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
We describe a single, large SCN5A-linked family with phenotypic characteristics of both LQT₃ and Brugada syndrome in the same patients. QT-interval prolongation and abnormal T-wave configuration are seen particularly at slow heart rates, and as shown previously in individual patients in this family, normalization occurs as rate increases.¹² Similar steep APD- and QT-rate relationships have been observed in LQT₃ patients⁷ and in experimental models mimicking LQT₃.¹⁷ It is likely that normal K⁺ currents result in physiological or supraphysiological cardiac repolarization during fast rates in these patients. In contrast, incomplete inactivation of I_Na (as a result of mutation in the SCN5A gene) results in abnormal repolarization at slow rates.^{7 9} Further compounding the QT abnormality is the bradycardia seen in affected patients (Figure 4), as has been reported for other LQT₃ patients.¹⁰ It is likely that these bradycardia-induced QT-interval abnormalities and resultant torsade de pointes underlie the high incidence of nocturnal sudden death in this and other LQT₃ families.^{7 8} Alternatively, a high vagal tone, likely of importance in Brugada syndrome–related ventricular fibrillation (see below),¹⁸ may be causally related to nocturnal death in this family.

The Brugada syndrome is characterized by right precordial ST-segment elevation with or without apparent right ventricular conduction delay.^{5 6 19} More general, mild, intraventricular conduction defects are usually also present, manifested by prolonged HV intervals and abnormal QRS axes.⁸ The ST abnormalities can be transient and can be modified by pharmacological interventions. Brugada syndrome patients present with syncope or out-of-hospital cardiac arrest and may have a family history of sudden cardiac death. Asymptomatic individuals appear to have a poor prognosis.⁵ Sudden cardiac death and documented episodes of ventricular fibrillation without antecedent QT abnormalities occur preferentially at night. This is especially the case in the syndrome of sudden unexplained death in young South-Asian men, which appears to be part of the clinical spectrum.²⁰ Causally related enhancement of vagal tone, just before the (fatal) arrhythmia, has been suggested,¹⁸ and acetylcholine augments the ST-segment changes.²¹ Note that 1 of our patients died suddenly while being shaved (potentially a carotis sinus massage, which may increase vagal tone). In the family, significant ST-segment elevation was present in 49% of patients. Procainamide exaggerated the effects in the 3 patients in which it was tested (Figure 3). In addition, intraventricular conduction defects (prolonged QRS and HV interval, late potentials) were generally present. Although the conduction delay is mild, the concomitant presence of both PR and QRS conduction delay in a significant subset of affected patients (Figure 5A) suggests a hampered conduction in different cardiac compartments. These features are all compatible with the Brugada syndrome diagnosis. Importantly, 16 affected subjects displayed both right precordial ST-segment elevation and QT-prolongation (Figures 3 and 5B).

In affected family members, 3 nucleotides (TGA) were inserted at nucleotide position 5537. This mutation gives rise to the insertion of a charged amino acid (Asp) after residue 1795 in the C-terminal end of the subunit of the Na⁺ channel (1795insD). No further abnormalities were found in SCN5A. LQT₃ (by definition) and Brugada syndrome are allelic disorders with involvement of SCN5A.^{2 3} Mutations in the C-terminal end have been linked to both syndromes in individual families or patients.^{10 11} The typical ECG features associated with the Brugada syndrome, as well as the ventricular and atrial conduction delays in 1795insD-affected patients, suggest a reduction in I_Na amplitude. It can be postulated that the balance between inward and outward currents during the characteristic phase 1 of the epicardial action potential may be shifted toward (enhanced) repolarization by the reduction in I_Na amplitude. Loss of the epicardial action potential plateau phase may ensue and cause transmural heterogeneity and ST elevation as a result of transmural current flow from endocardium to epicardium.^{6 22} The functional consequences of 1795insD may particularly affect the contribution of the right ventricle, where epicardial action potentials are proportionately well represented and exhibit a particularly well established "spike and dome morphology."²³ Indeed, in our and other patients with the Brugada syndrome,^{6 21} reduction of I_Na by Na⁺ channel blockers augments the ST-segment abnormalities (Figure 3). The results from our expression study are in line with a reduced Na⁺ current. We found a 7.3-mV negative shift of the steady-state inactivation curve and an 8.1-mV positive shift of the steady-state activation curve of the 1795insD mutant channels. The functional consequence of both shifts is likely to be a reduced Na⁺ current during the upstroke and phase 1 of the action potential. Moreover, 1795insD Na⁺ currents had 5-fold smaller amplitudes than WT currents, which is less than expected on ground of the shifts in activation- and inactivation curves alone. It suggests the presence of additional differences, such as a reduced Na⁺ channel density or conductance. Our findings are different from functional characterization of the Brugada syndrome SCN5A mutations described so far. These included faster recovery from inactivation and a negative shift of the steady-state activation curve.^{3 11}

It is difficult to link the prolonged QT interval in these patients to the observed kinetic characteristics of the 1795insD mutant channel. In general, prolongation of the repolarization process suggests an increase in net inward current during the plateau phase of the action potential. Indeed, it has been shown that persistent inward Na⁺ current, secondary to incomplete inactivation, underlies LQT₃.⁹ Analysis of procainamide- and tetrodotoxin-sensitive currents did not reveal such a persistent Na⁺ current in our study. The observed small increase in inactivation time constants is probably not sufficient to account for the prolonged QT interval, certainly not in view of the overall reduction in I_Na amplitude.

To ultimately decide on the presence (or absence) of a persistent inward current, further experiments are needed. Several factors may have hampered its detection in the present study. First, experiments were performed at room temperature. It has been shown that the kinetics of both WT and KPQ Na⁺ channels are highly sensitive to temperature, having 2-fold faster activation and inactivation kinetics at 33°C compared with 23°C and a positive shift of the activation and steady-state inactivation at the higher temperature.²⁴ Second, ion channel properties may be dependent on the expression system.²⁵ In the present study Na⁺ channels were expressed in a nonmammalian system. Third, it has been shown that the nearby D1790G and E1784K mutations affect the voltage dependence of I_Na inactivation by altered interaction between the and ß₁ subunit.^{10 26} Interaction of the ß₁ subunit with the subunit also significantly affects I_Na amplitude.²⁷ Hence, it is conceivable that coexpression of the ß₁ subunit with the 1795insD mutant subunit uncovers kinetic properties of the channel that may give rise to prolongation of the repolarization process. In this respect it should be noted, however, that coexpression of the subunit with the ß₁ subunit did not affect the persistent inward current in case of the E1784K mutant.²⁶ Finally, single-channel measurements in multichannel patches may be used to reveal late openings indicative for the presence of a persistent current.

In summary, we describe a large SCN5A-linked family, characterized by QT prolongation, in particular during bradycardia; discrete conduction disturbances throughout the heart; and nocturnal sudden cardiac death. Electrocardiographic features of LQT₃ and Brugada syndrome are present in the same (affected) individuals, demonstrating that LQT₃ and Brugada syndrome are more closely related than heretofore appreciated. Both syndromes can even be caused by the same mutation.

	Acknowledgments

 
This work was supported by Grant D95/014 from the Dutch Heart Foundation. We are indebted to the family members for their participation. We thank Dr Antoinette Groenewegen for help with the expression studies and helpful discussions. We thank Hester Cazemier, Muriël Blok, Joke Verheij, and Marriëtte Schipper for their help in establishing the pedigree and linkage analysis and for their efforts in collecting patient material. In addition, we are grateful to Drs J.H. Cornel (Medisch Centrum Alkmaar, the Netherlands), R.W. Breedveld (Medisch Centrum Leeuwarden, the Netherlands), M.R. van der Linde and J.J. de Graaf (Nij Smellinge, Drachten, the Netherlands), and E.W. van der Toren (Sionsberg, Dokkum, the Netherlands). Dr Dan Roden (Nashville, TN) is gratefully acknowledged for his critical reading of the manuscript.

	Footnotes

 
¹ Both authors contributed equally to this study.

Received July 8, 1999; accepted September 26, 1999.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Gellens ME, George AL, Chen L, Chahine M, Horn R, Barchi RL, Kallen RG. Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. Proc Nat Acad Sci U S A. 1992;89:554–558.[Abstract/Free Full Text]

2. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805–811.[Medline] [Order article via Infotrieve]

3. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O’Brien RE, Schulze-Bahr E, Keating MT, Towbin JA, Wang Q. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392:293–296.[Medline] [Order article via Infotrieve]

4. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson MS, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH, Keating MT, MacCluer JW, Timothy KW. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995;92:2929–2934.[Abstract/Free Full Text]

5. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation. 1998;97:457–460.[Abstract/Free Full Text]

6. Alings M, Wilde A. "Brugada" syndrome: clinical data and suggested pathophysiological mechanism. Circulation. 1999;99:666–673.[Free Full Text]

7. Schwartz PJ, Priori SG, Locati E, Napolitano C, Cantum F, Towbin JA, Keating MT, Hammoude H, Brown AM, Chen LSK, Colatsky TJ. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na⁺ channel blockade and to increases in heart rate. Circulation. 1995;92:3381–3386.[Abstract/Free Full Text]

8. Schwartz PJ, Moss AJ, Priori SG, Wang Q, Lehmann MH, Timothy KW, Denjoy IF, Haverkamp W, Guicheney P, Paganini V, Scheinmann MM, Kames PS. Gene-specific influence on the triggers for cardiac arrest in the long QT syndrome. Circulation. 1997;96 (suppl I):I-212. Abstract.

9. Bennett PB, Yazawa K, Makita N, George AL. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995;376:683–685.[Medline] [Order article via Infotrieve]

10. An RH, Wang XL, Kerem B, Benhorin J, Medina A, Goldmit M, Kass RS. Novel LQT-3 mutation affects Na⁺ channel activity through interactions between -and ß₁ subunits. Circ Res. 1998;83:141–146.[Abstract/Free Full Text]

11. Rook MB, Alshinawi C, Groenewegen A, van Ginneken ACG, Jongsma HJ, van Gelder I, Mannens MMAM, Wilde AAM. Human SCN5A gene mutations alter Na-current kinetics and associate with VF in patients without structural heart disease. Circulation. 1998;98(suppl I):I-468. Abstract.

12. Tobé TJM, de Langen CDJ, Bink-Boelkens MTE, Mook PH, Viersma JW, Lie KI, Wesseling H. Late potentials in a bradycardia-dependent Long QT syndrome associated with sudden death during sleep. J Am Coll Cardiol. 1992;19:541–549.[Abstract]

13. Wang Q, Li Z, Shen J, Keating MT. Genomic organization of the human SCN5A gene encoding the cardiac sodium channel. Genomics. 1996;34:9–16.[Medline] [Order article via Infotrieve]

14. Makita N, Bennet PB, George AL. Multiple domains contribute to the distinct inactivation properties of human heart and skeletal muscle Na⁺ channels. Circ Res. 1996;78:244–252.[Abstract/Free Full Text]

15. Stühmer W. Electrophysiological recording from Xenopus oocytes. Methods Enzymol. 1992;207:319–339.[Medline] [Order article via Infotrieve]

16. Wang DW, Yazawa K, George AL, Bennett PB. Characterization of human cardiac Na⁺ channel mutations in the congenital long QT syndrome. Proc Natl Acad Sci U S A. 1996;93:13200–13205.[Abstract/Free Full Text]

17. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsades de pointes in LQT2 and LQT3 models of the long QT syndrome. Circulation. 1997;96:2038–2047.[Abstract/Free Full Text]

18. Kasanuki H, Ohnishi S, Ohtuka M, Matsuda N, Nirei T, Isogai R, Shoda M, Toyoshima Y, Hosoda S. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation. 1997;95:2277–2285.[Abstract/Free Full Text]

19. Brugada P, Brugada J. Right bundle branch block, persistent ST-segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. J Am Coll Cardiol. 1992;20:1391–1396.[Abstract]

20. Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo K, Likittanasombat K, Tunsanga K, Kuasirikul S, Malasit P, Tansupasawadikul S, Tatsanavivat P. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation. 1997;96:2595–2600.[Abstract/Free Full Text]

21. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol. 1996;27:1061–1070.[Abstract]

22. Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol. 1998;9:513–516.[Medline] [Order article via Infotrieve]

23. DiDiego JM, Sun ZQ, Antzelevitch C. I_to and action potential notch are smaller in left vs. right canine ventricular epicardium. Am J Physiol. 1996;271:H548–H561.[Abstract/Free Full Text]

24. Nagatomo T, Fan Z, Ye B, Tonkovich GS, January GT, Kyle WJ, Makielski JC. Temperature dependence of early and late currents in human cardiac wild-type and long Q-T KPQ Na⁺ channels. Am J Physiol. 1998;275:H2016–H2024.[Abstract/Free Full Text]

25. Lewis TM, Harkness PC, Sivilotti LG, Colquhoun D, Millar NS. The ion channel properties of a rat recombinant neuronal nicotinic receptor are dependent on the host cell type. J Physiol. 1997;505:299–306.[Abstract/Free Full Text]

26. Wei J, Wang DW, Alings M, Fish F, Wathen M, Roden DM, George AL. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na⁺ channel. Circulation. 1999;99:3165–3171.[Abstract/Free Full Text]

27. Kupershmidt S, Yang T, Roden DM. Modulation of cardiac Na⁺ current phenotype by ß₁-subunit expression. Circ Res. 1998;83:441–447.[Abstract/Free Full Text]

This article has been cited by other articles:

				A. L. George Jr Genetic Modulation of Impaired Cardiac Conduction: Sodium Channel {beta}4 Subunit Missing in Action Circ. Res., June 5, 2009; 104(11): 1238 - 1239. [Full Text] [PDF]

				C. A. Remme, B. P. Scicluna, A. O. Verkerk, A. S. Amin, S. van Brunschot, L. Beekman, V. H.M. Deneer, C. Chevalier, F. Oyama, H. Miyazaki, et al. Genetically Determined Differences in Sodium Current Characteristics Modulate Conduction Disease Severity in Mice With Cardiac Sodium Channelopathy Circ. Res., June 5, 2009; 104(11): 1283 - 1292. [Abstract] [Full Text] [PDF]

				S. Biswas, D. DiSilvestre, Y. Tian, V. L. Halperin, and G. F. Tomaselli Calcium-Mediated Dual-Mode Regulation of Cardiac Sodium Channel Gating Circ. Res., April 10, 2009; 104(7): 870 - 878. [Abstract] [Full Text] [PDF]

				V. Z. Miloushev, J. A. Levine, M. A. Arbing, J. F. Hunt, G. S. Pitt, and A. G. Palmer III Solution Structure of the NaV1.2 C-terminal EF-hand Domain J. Biol. Chem., March 6, 2009; 284(10): 6446 - 6454. [Abstract] [Full Text] [PDF]

				R. Shi, Y. Zhang, C. Yang, C. Huang, X. Zhou, H. Qiang, A. A. Grace, C. L.-H. Huang, and A. Ma The cardiac sodium channel mutation delQKP 1507-1509 is associated with the expanding phenotypic spectrum of LQT3, conduction disorder, dilated cardiomyopathy, and high incidence of youth sudden death Europace, November 1, 2008; 10(11): 1329 - 1335. [Abstract] [Full Text] [PDF]

				C. A. Remme and A. A.M. Wilde SCN5A overlap syndromes: no end to disease complexity? Europace, November 1, 2008; 10(11): 1253 - 1255. [Full Text] [PDF]

				A. A. M. Wilde and R. Coronel The complexity of genotype-phenotype relations associated with loss-of-function sodium channel mutations and the role of in silico studies Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H8 - H9. [Full Text] [PDF]

				M. Bebarova, T. O'Hara, J. L. M. C. Geelen, R. J. Jongbloed, C. Timmermans, Y. H. Arens, L.-M. Rodriguez, Y. Rudy, and P. G. A. Volders Subepicardial phase 0 block and discontinuous transmural conduction underlie right precordial ST-segment elevation by a SCN5A loss-of-function mutation Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H48 - H58. [Abstract] [Full Text] [PDF]

				L. Baty, J. Hollister, and J. D. Tobias Perioperative Management of a 7-Year-Old Child With Brugada Syndrome J Intensive Care Med, May 1, 2008; 23(3): 210 - 214. [Abstract] [PDF]

				D. Darbar, P. J. Kannankeril, B. S. Donahue, G. Kucera, T. Stubblefield, J. L. Haines, A. L. George Jr, and D. M. Roden Cardiac Sodium Channel (SCN5A) Variants Associated with Atrial Fibrillation Circulation, April 15, 2008; 117(15): 1927 - 1935. [Abstract] [Full Text] [PDF]

				S. Nagase, K. F. Kusano, H. Morita, N. Nishii, K. Banba, A. Watanabe, S. Hiramatsu, K. Nakamura, S. Sakuragi, and T. Ohe Longer Repolarization in the Epicardium at the Right Ventricular Outflow Tract Causes Type 1 Electrocardiogram in Patients With Brugada Syndrome J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1154 - 1161. [Abstract] [Full Text] [PDF]

				R. Surber, S. Hensellek, D. Prochnau, G. S. Werner, K. Benndorf, H. R. Figulla, and T. Zimmer Combination of cardiac conduction disease and long QT syndrome caused by mutation T1620K in the cardiac sodium channel Cardiovasc Res, March 1, 2008; 77(4): 740 - 748. [Abstract] [Full Text] [PDF]

				T. P. Nguyen, D. W. Wang, T. H. Rhodes, and A. L. George Jr Divergent Biophysical Defects Caused by Mutant Sodium Channels in Dilated Cardiomyopathy With Arrhythmia Circ. Res., February 15, 2008; 102(3): 364 - 371. [Abstract] [Full Text] [PDF]

				H. Abriel Roles and regulation of the cardiac sodium channel Nav1.5: Recent insights from experimental studies Cardiovasc Res, December 1, 2007; 76(3): 381 - 389. [Abstract] [Full Text] [PDF]

				B.-H. Tan, P. Iturralde-Torres, A. Medeiros-Domingo, S. Nava, D. J. Tester, C. R. Valdivia, T. Tusie-Luna, M. J. Ackerman, and J. C. Makielski A novel C-terminal truncation SCN5A mutation from a patient with sick sinus syndrome, conduction disorder and ventricular tachycardia Cardiovasc Res, December 1, 2007; 76(3): 409 - 417. [Abstract] [Full Text] [PDF]

				S. Casini, H. L. Tan, Z. A. Bhuiyan, C. R. Bezzina, P. Barnett, E. Cerbai, A. Mugelli, A. A.M. Wilde, and M. W. Veldkamp Characterization of a novel SCN5A mutation associated with Brugada syndrome reveals involvement of DIIIS4-S5 linker in slow inactivation Cardiovasc Res, December 1, 2007; 76(3): 418 - 429. [Abstract] [Full Text] [PDF]

				S. E. Lehnart, M. J. Ackerman, D. W. Benson Jr, R. Brugada, C. E. Clancy, J. K. Donahue, A. L. George Jr, A. O. Grant, S. C. Groft, C. T. January, et al. Inherited Arrhythmias: A National Heart, Lung, and Blood Institute and Office of Rare Diseases Workshop Consensus Report About the Diagnosis, Phenotyping, Molecular Mechanisms, and Therapeutic Approaches for Primary Cardiomyopathies of Gene Mutations Affecting Ion Channel Function Circulation, November 13, 2007; 116(20): 2325 - 2345. [Abstract] [Full Text] [PDF]

				N. H. Robin, P. B. Tabereaux, R. Benza, and B. R. Korf Genetic Testing in Cardiovascular Disease J. Am. Coll. Cardiol., August 21, 2007; 50(8): 727 - 737. [Abstract] [Full Text] [PDF]

				G. Frigo, A. Rampazzo, B. Bauce, K. Pilichou, G. Beffagna, G. A. Danieli, A. Nava, and B. Martini Homozygous SCN5A mutation in Brugada syndrome with monomorphic ventricular tachycardia and structural heart abnormalities Europace, June 1, 2007; 9(6): 391 - 397. [Abstract] [Full Text] [PDF]

				M. Lei, H. Zhang, A. A. Grace, and C. L.-H. Huang SCN5A and sinoatrial node pacemaker function Cardiovasc Res, June 1, 2007; 74(3): 356 - 365. [Abstract] [Full Text] [PDF]

				H. Dobrzynski, M. R. Boyett, and R. H. Anderson New Insights Into Pacemaker Activity: Promoting Understanding of Sick Sinus Syndrome Circulation, April 10, 2007; 115(14): 1921 - 1932. [Full Text] [PDF]

				L. S. Maier and D. M. Bers Role of Ca2+/calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart Cardiovasc Res, March 1, 2007; 73(4): 631 - 640. [Abstract] [Full Text] [PDF]

				C. A. Remme, A. O. Verkerk, D. Nuyens, A. C. G. van Ginneken, S. van Brunschot, C. N. W. Belterman, R. Wilders, M. A. van Roon, H. L. Tan, A. A. M. Wilde, et al. Overlap Syndrome of Cardiac Sodium Channel Disease in Mice Carrying the Equivalent Mutation of Human SCN5A-1795insD Circulation, December 12, 2006; 114(24): 2584 - 2594. [Abstract] [Full Text] [PDF]

				D.-M. Niu, B. Hwang, H.-W. Hwang, N. H Wang, J.-Y. Wu, P.-C. Lee, J.-C. Chien, R.-C. Shieh, and Y.-T. Chen A common SCN5A polymorphism attenuates a severe cardiac phenotype caused by a nonsense SCN5A mutation in a Chinese family with an inherited cardiac conduction defect J. Med. Genet., October 1, 2006; 43(10): 817 - 821. [Abstract] [Full Text] [PDF]

				I. W. Glaaser, J. R. Bankston, H. Liu, M. Tateyama, and R. S. Kass A Carboxyl-terminal Hydrophobic Interface Is Critical to Sodium Channel Function: Relevance to Inherited Disorders J. Biol. Chem., August 18, 2006; 281(33): 24015 - 24023. [Abstract] [Full Text] [PDF]

				J. Castro Hevia, C. Antzelevitch, F. Tornes Barzaga, M. Dorantes Sanchez, F. Dorticos Balea, R. Zayas Molina, M. A. Quinones Perez, and Y. Fayad Rodriguez Tpeak-Tend and Tpeak-Tend Dispersion as Risk Factors for Ventricular Tachycardia/Ventricular Fibrillation in Patients With the Brugada Syndrome J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1828 - 1834. [Abstract] [Full Text] [PDF]

				W. Creighton, R. Virmani, R. Kutys, and A. Burke Identification of Novel Missense Mutations of Cardiac Ryanodine Receptor Gene in Exercise-Induced Sudden Death at Autopsy J. Mol. Diagn., February 1, 2006; 8(1): 62 - 67. [Abstract] [Full Text] [PDF]

				T. Makiyama, M. Akao, K. Tsuji, T. Doi, S. Ohno, K. Takenaka, A. Kobori, T. Ninomiya, H. Yoshida, M. Takano, et al. High Risk for Bradyarrhythmic Complications in Patients With Brugada Syndrome Caused by SCN5A Gene Mutations J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2100 - 2106. [Abstract] [Full Text] [PDF]

				M. Shah, F. G. Akar, and G. F. Tomaselli Molecular Basis of Arrhythmias Circulation, October 18, 2005; 112(16): 2517 - 2529. [Abstract] [Full Text] [PDF]

				J. M. Nerbonne and R. S. Kass Molecular Physiology of Cardiac Repolarization Physiol Rev, October 1, 2005; 85(4): 1205 - 1253. [Abstract] [Full Text] [PDF]

				W. Ulbricht Sodium Channel Inactivation: Molecular Determinants and Modulation Physiol Rev, October 1, 2005; 85(4): 1271 - 1301. [Abstract] [Full Text] [PDF]

				A. A M Wilde and C. R Bezzina Genetics of cardiac arrhythmias Heart, October 1, 2005; 91(10): 1352 - 1358. [Full Text] [PDF]

				P. G. Meregalli, A. A.M. Wilde, and H. L. Tan Pathophysiological mechanisms of Brugada syndrome: Depolarization disorder, repolarization disorder, or more? Cardiovasc Res, August 15, 2005; 67(3): 367 - 378. [Abstract] [Full Text] [PDF]

				J. P.P. Smits, M. W. Veldkamp, C. R. Bezzina, Z. A. Bhuiyan, H. Wedekind, E. Schulze-Bahr, and A. A.M. Wilde Substitution of a conserved alanine in the domain IIIS4-S5 linker of the cardiac sodium channel causes long QT syndrome Cardiovasc Res, August 15, 2005; 67(3): 459 - 466. [Abstract] [Full Text] [PDF]

				A. Burke, W. Creighton, E. Mont, L. Li, S. Hogan, R. Kutys, D. Fowler, and R. Virmani Role of SCN5A Y1102 Polymorphism in Sudden Cardiac Death in Blacks Circulation, August 9, 2005; 112(6): 798 - 802. [Abstract] [Full Text] [PDF]

				G. C.M. Beaufort-Krol, M. P. van den Berg, A. A.M. Wilde, J. P. van Tintelen, J. W. Viersma, C. R. Bezzina, and M. Th.E. Bink-Boelkens Developmental Aspects of Long QT Syndrome Type 3 and Brugada Syndrome on the Basis of a Single SCN5A Mutation in Childhood J. Am. Coll. Cardiol., July 19, 2005; 46(2): 331 - 337. [Abstract] [Full Text] [PDF]

				H. L. Tan, N. Hofman, I. M. van Langen, A. C. van der Wal, and A. A.M. Wilde Sudden Unexplained Death: Heritability and Diagnostic Yield of Cardiological and Genetic Examination in Surviving Relatives Circulation, July 12, 2005; 112(2): 207 - 213. [Abstract] [Full Text] [PDF]

				T. Chen, M. Inoue, and M. F. Sheets Reduced voltage dependence of inactivation in the SCN5A sodium channel mutation delF1617 Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2666 - H2676. [Abstract] [Full Text] [PDF]

				C. Antzelevitch, P. Brugada, M. Borggrefe, J. Brugada, R. Brugada, D. Corrado, I. Gussak, H. LeMarec, K. Nademanee, A. R. Perez Riera, et al. Brugada Syndrome: Report of the Second Consensus Conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association Circulation, February 8, 2005; 111(5): 659 - 670. [Abstract] [Full Text] [PDF]

				J.-S. Hermida, I. Denjoy, J. Clerc, F. Extramiana, G. Jarry, P. Milliez, P. Guicheney, S. Di Fusco, J.-L. Rey, B. Cauchemez, et al. Hydroquinidine therapy in Brugada syndrome J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1853 - 1860. [Abstract] [Full Text] [PDF]

				E. F. D. Wever and E. O. Robles de Medina Sudden death in patients without structural heart disease J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1137 - 1144. [Abstract] [Full Text] [PDF]

				A. G. KLEBER and Y. RUDY Basic Mechanisms of Cardiac Impulse Propagation and Associated Arrhythmias Physiol Rev, April 1, 2004; 84(2): 431 - 488. [Abstract] [Full Text] [PDF]

				S. G. Priori Inherited Arrhythmogenic Diseases: The Complexity Beyond Monogenic Disorders Circ. Res., February 6, 2004; 94(2): 140 - 145. [Abstract] [Full Text] [PDF]

				C. Napolitano Transgenic models in cardiac arrhythmias: how close can we get to the bedside? Cardiovasc Res, February 1, 2004; 61(2): 206 - 207. [Full Text] [PDF]

				H. K. Motoike, H. Liu, I. W. Glaaser, A.-S. Yang, M. Tateyama, and R. S. Kass The Na+ Channel Inactivation Gate Is a Molecular Complex: A Novel Role of the COOH-terminal Domain J. Gen. Physiol., January 26, 2004; 123(2): 155 - 165. [Abstract] [Full Text] [PDF]

				M. W. Veldkamp, R. Wilders, A. Baartscheer, J. G. Zegers, C. R. Bezzina, and A. A.M. Wilde Contribution of Sodium Channel Mutations to Bradycardia and Sinus Node Dysfunction in LQT3 Families Circ. Res., May 16, 2003; 92(9): 976 - 983. [Abstract] [Full Text] [PDF]

				K. Nademanee, G. Veerakul, M. Mower, K. Likittanasombat, R. Krittayapong, K. Bhuripanyo, S. Sitthisook, L. Chaothawee, M. Y. Lai, and S. P. Azen Defibrillator Versus {beta}-Blockers for Unexplained Death in Thailand (DEBUT): A Randomized Clinical Trial Circulation, May 6, 2003; 107(17): 2221 - 2226. [Abstract] [Full Text] [PDF]

				H. L Tan, C. R Bezzina, J. P.P Smits, A. O Verkerk, and A. A.M Wilde Genetic control of sodium channel function Cardiovasc Res, March 15, 2003; 57(4): 961 - 973. [Abstract] [Full Text] [PDF]

				W.A. Groenewegen, C. R. Bezzina, J.P. van Tintelen, T. M. Hoorntje, M. M.A.M. Mannens, A. A.M. Wilde, Habo.J. Jongsma, and M. B. Rook A novel LQT3 mutation implicates the human cardiac sodium channel domain IVS6 in inactivation kinetics Cardiovasc Res, March 15, 2003; 57(4): 1072 - 1078. [Abstract] [Full Text] [PDF]

				C. R. Bezzina, M. B. Rook, W.A. Groenewegen, L. J. Herfst, A. C. van der Wal, J. Lam, H. J. Jongsma, A. A.M. Wilde, and M. M.A.M. Mannens Compound Heterozygosity for Mutations (W156X and R225W) in SCN5A Associated With Severe Cardiac Conduction Disturbances and Degenerative Changes in the Conduction System Circ. Res., February 7, 2003; 92(2): 159 - 168. [Abstract] [Full Text] [PDF]

				B. Ye, C. R. Valdivia, M. J. Ackerman, and J. C. Makielski A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation Physiol Genomics, February 6, 2003; 12(3): 187 - 193. [Abstract] [Full Text] [PDF]

				M. Firouzi and W. A. Groenewegen Gene polymorphisms and cardiac arrhythmias Europace, January 1, 2003; 5(3): 235 - 242. [Full Text] [PDF]

				E. Moric, E. Herbert, M. Trusz-Gluza, A. Filipecki, U. Mazurek, and T. Wilczok The implications of genetic mutations in the sodium channel gene (SCN5A) Europace, January 1, 2003; 5(4): 325 - 334. [Abstract] [Full Text] [PDF]

				A. A.M. Wilde, C. Antzelevitch, M. Borggrefe, J. Brugada, R. Brugada, P. Brugada, D. Corrado, R. N.W. Hauer, R. S. Kass, K. Nademanee, et al. Proposed Diagnostic Criteria for the Brugada Syndrome: Consensus Report Circulation, November 5, 2002; 106(19): 2514 - 2519. [Full Text] [PDF]

				A.A.M. Wilde, C. Antzelevitch, M. Borggrefe, J. Brugada, R. Brugada, P. Brugada, D. Corrado, R.N.W. Hauer, R.S. Kass, K. Nademanee, et al. Proposed Diagnostic Criteria for the Brugada Syndrome Eur. Heart J., November 1, 2002; 23(21): 1648 - 1654. [Full Text] [PDF]

				N. Makita, M. Horie, T. Nakamura, T. Ai, K. Sasaki, H. Yokoi, M. Sakurai, I. Sakuma, H. Otani, H. Sawa, et al. Drug-Induced Long-QT Syndrome Associated With a Subclinical SCN5A Mutation Circulation, September 3, 2002; 106(10): 1269 - 1274. [Abstract] [Full Text] [PDF]

				T. Chen and M. F. Sheets Enhancement of closed-state inactivation in long QT syndrome sodium channel mutation Delta KPQ Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H966 - H975. [Abstract] [Full Text] [PDF]

				C. R Bezzina and H. L Tan Pharmacological rescue of mutant ion channels Cardiovasc Res, August 1, 2002; 55(2): 229 - 232. [Full Text] [PDF]

				C. R Valdivia, M. J Ackerman, D. J Tester, T. Wada, J. McCormack, B. Ye, and J. C Makielski A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine Cardiovasc Res, August 1, 2002; 55(2): 279 - 289. [Abstract] [Full Text] [PDF]

				T. Kurita, W. Shimizu, M. Inagaki, K. Suyama, A. Taguchi, K. Satomi, N. Aihara, S. Kamakura, J. Kobayashi, and Y. Kosakai The electrophysiologic mechanism of ST-segment elevation in Brugada syndrome J. Am. Coll. Cardiol., July 17, 2002; 40(2): 330 - 334. [Abstract] [Full Text] [PDF]

				D. M. Roden The problem, challenge and opportunity of genetic heterogeneity in monogenic diseases predisposing to sudden death J. Am. Coll. Cardiol., July 17, 2002; 40(2): 357 - 359. [Full Text] [PDF]

				H. Liu, M. Tateyama, C. E. Clancy, H. Abriel, and R. S. Kass Channel Openings Are Necessary but not Sufficient for Use-dependent Block of Cardiac Na+ Channels by Flecainide: Evidence from the Analysis of Disease-linked Mutations J. Gen. Physiol., June 24, 2002; 120(1): 39 - 51. [Abstract] [Full Text] [PDF]

				C. Antzelevitch Late potentials and the Brugada syndrome J. Am. Coll. Cardiol., June 19, 2002; 39(12): 1996 - 1999. [Full Text] [PDF]

				T. Nagatomo, C. T. January, B. Ye, H. Abe, Y. Nakashima, and J. C. Makielski Rate-dependent QT shortening mechanism for the LQT3 {Delta}KPQ mutant Cardiovasc Res, June 1, 2002; 54(3): 624 - 629. [Abstract] [Full Text] [PDF]

				A.A.M. Wilde, C.A. Remme, R. Derksen, E.F.D. Wever, and R.N.W. Hauer Brugada syndrome Eur. Heart J., April 2, 2002; 23(8): 675 - 676. [Full Text] [PDF]

				J. R. Balser Inherited sodium channelopathies: models for acquired arrhythmias? Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1175 - H1180. [Full Text] [PDF]

				J. W. Cormier, I. Rivolta, M. Tateyama, A.-S. Yang, and R. S. Kass Secondary Structure of the Human Cardiac Na+ Channel C Terminus. EVIDENCE FOR A ROLE OF HELICAL STRUCTURES IN MODULATION OF CHANNEL INACTIVATION J. Biol. Chem., March 8, 2002; 277(11): 9233 - 9241. [Abstract] [Full Text] [PDF]

				I. Deschenes, N. Neyroud, D. DiSilvestre, E. Marban, D. T. Yue, and G. F. Tomaselli Isoform-Specific Modulation of Voltage-Gated Na+ Channels by Calmodulin Circ. Res., March 8, 2002; 90 (4): e49 - e57. [Abstract] [Full Text] [PDF]

				M. Vatta, R. Dumaine, G. Varghese, T. A. Richard, W. Shimizu, N. Aihara, K. Nademanee, R. Brugada, J. Brugada, G. Veerakul, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome Hum. Mol. Genet., February 1, 2002; 11(3): 337 - 345. [Abstract] [Full Text] [PDF]

				N. Shirai, N. Makita, K. Sasaki, H. Yokoi, I. Sakuma, H. Sakurada, J. Akai, A. Kimura, M. Hiraoka, and A. Kitabatake A mutant cardiac sodium channel with multiple biophysical defects associated with overlapping clinical features of Brugada syndrome and cardiac conduction disease Cardiovasc Res, February 1, 2002; 53(2): 348 - 354. [Abstract] [Full Text] [PDF]

				R. Brugada and R. Roberts Brugada Syndrome: Why Are There Multiple Answers to a Simple Question? Circulation, December 18, 2001; 104(25): 3017 - 3019. [Full Text] [PDF]

				F. Kyndt, V. Probst, F. Potet, S. Demolombe, J.-C. Chevallier, I. Baro, J.-P. Moisan, P. Boisseau, J.-J. Schott, D. Escande, et al. Novel SCN5A Mutation Leading Either to Isolated Cardiac Conduction Defect or Brugada Syndrome in a Large French Family Circulation, December 18, 2001; 104(25): 3081 - 3086. [Abstract] [Full Text] [PDF]

				S Sangwatanaroj, S Prechawat, B Sunsaneewitayakul, S Sitthisook, P Tosukhowong, and K Tungsanga New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives Eur. Heart J., December 2, 2001; 22(24): 2290 - 2296. [Abstract] [PDF]

				P Syrris, A Murray, N D Carter, W M McKenna, and S Jeffery Mutation detection in long QT syndrome: a comprehensive set of primers and PCR conditions J. Med. Genet., October 1, 2001; 38(10): 705 - 710. [Full Text] [PDF]

				P. C. Viswanathan, C. R. Bezzina, A. L. George Jr., D. M. Roden, A. A.M. Wilde, and J. R. Balser Gating-Dependent Mechanisms for Flecainide Action in SCN5A-Linked Arrhythmia Syndromes Circulation, September 4, 2001; 104(10): 1200 - 1205. [Abstract] [Full Text] [PDF]

				P. M. Spooner, C. Albert, E. J. Benjamin, R. Boineau, R. C. Elston, A. L. George Jr, X. Jouven, L. H. Kuller, J. W. MacCluer, E. Marban, et al. Sudden Cardiac Death, Genes, and Arrhythmogenesis : Consideration of New Population and Mechanistic Approaches From a National Heart, Lung, and Blood Institute Workshop, Part I Circulation, May 15, 2001; 103(19): 2361 - 2364. [Abstract] [Full Text] [PDF]

				I. Gussak, P. Bjerregaard, and S. C. Hammill Clinical diagnosis and risk stratification in patients with brugada syndrome J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1635 - 1638. [Full Text] [PDF]

				C Antzelevitch The Brugada syndrome: diagnostic criteria and cellular mechanisms Eur. Heart J., March 1, 2001; 22(5): 356 - 363. [PDF]

				C. R Bezzina, M. B Rook, and A. A.M Wilde Cardiac sodium channel and inherited arrhythmia syndromes Cardiovasc Res, February 1, 2001; 49(2): 257 - 271. [Full Text] [PDF]

				X. Wan, S. Chen, A. Sadeghpour, Q. Wang, and G. E. Kirsch Accelerated inactivation in a mutant Na+ channel associated with idiopathic ventricular fibrillation Am J Physiol Heart Circ Physiol, January 1, 2001; 280(1): H354 - H360. [Abstract] [Full Text] [PDF]

				D. W. Wang, N. Makita, A. Kitabatake, J. R. Balser, and A. L. George Jr Enhanced Na+ Channel Intermediate Inactivation in Brugada Syndrome Circ. Res., October 13, 2000; 87 (8): e37 - e43. [Abstract] [Full Text] [PDF]

				I. Splawski, J. Shen, K. W. Timothy, M. H. Lehmann, S. Priori, J. L. Robinson, A. J. Moss, P. J. Schwartz, J. A. Towbin, G. M. Vincent, et al. Spectrum of Mutations in Long-QT Syndrome Genes : KVLQT1, HERG, SCN5A, KCNE1, and KCNE2 Circulation, September 5, 2000; 102(10): 1178 - 1185. [Abstract] [Full Text] [PDF]

				S. G. Priori, C. Napolitano, P. J. Schwartz, R. Bloise, L. Crotti, and E. Ronchetti The Elusive Link Between LQT3 and Brugada Syndrome : The Role of Flecainide Challenge Circulation, August 29, 2000; 102(9): 945 - 947. [Abstract] [Full Text] [PDF]

				H. Abriel, X. H. T. Wehrens, J. Benhorin, B. Kerem, and R. S. Kass Molecular Pharmacology of the Sodium Channel Mutation D1790G Linked to the Long-QT Syndrome Circulation, August 22, 2000; 102(8): 921 - 925. [Abstract] [Full Text] [PDF]

				C.-E. Chiang and D. M. Roden The long QT syndromes: genetic basis and clinical implications J. Am. Coll. Cardiol., July 1, 2000; 36(1): 1 - 12. [Abstract] [Full Text] [PDF]

				M. W. Veldkamp, P. C. Viswanathan, C. Bezzina, A. Baartscheer, A. A. M. Wilde, and J. R. Balser Two Distinct Congenital Arrhythmias Evoked by a Multidysfunctional Na+ Channel Circ. Res., May 12, 2000; 86 (9): e91 - e97. [Abstract] [Full Text] [PDF]

				A. A.M. Wilde and M. W. Veldkamp What we can learn from individual resuscitated patients Cardiovasc Res, April 1, 2000; 46(1): 14 - 16. [Full Text] [PDF]

				I. Rivolta, H. Abriel, M. Tateyama, H. Liu, M. Memmi, P. Vardas, C. Napolitano, S. G. Priori, and R. S. Kass Inherited Brugada and Long QT-3 Syndrome Mutations of a Single Residue of the Cardiac Sodium Channel Confer Distinct Channel and Clinical Phenotypes J. Biol. Chem., August 10, 2001; 276(33): 30623 - 30630. [Abstract] [Full Text] [PDF]

				H. Abriel, C. Cabo, X. H. T. Wehrens, I. Rivolta, H. K. Motoike, M. Memmi, C. Napolitano, S. G. Priori, and R. S. Kass Novel Arrhythmogenic Mechanism Revealed by a Long-QT Syndrome Mutation in the Cardiac Na+ Channel Circ. Res., April 13, 2001; 88(7): 740 - 745. [Abstract] [Full Text] [PDF]

				C. E. Clancy and Y. Rudy Na+ Channel Mutation That Causes Both Brugada and Long-QT Syndrome Phenotypes: A Simulation Study of Mechanism Circulation, March 12, 2002; 105(10): 1208 - 1213. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Methods Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bezzina, C. Articles by Wilde, A. A. M. Search for Related Content PubMed PubMed Citation Articles by Bezzina, C. Articles by Wilde, A. A. M.